{
    "2019-12-03": [
        [
            {
                "time": "2018-12-03",
                "original_text": "Mylan (MYL) Launches Herceptin Biosimilar Ogivri in the US",
                "features": {
                    "keywords": [
                        "Mylan",
                        "Herceptin",
                        "Biosimilar",
                        "Ogivri",
                        "US"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-12-16",
                "original_text": "Gene-Therapy Firm Audentes Sells for Double Its Share Price. It Could Be the First of Many More Deals.",
                "features": {
                    "keywords": [
                        "Gene-Therapy",
                        "Audentes",
                        "Sells",
                        "Double",
                        "Share Price",
                        "Deals"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-11-22",
                "original_text": "Merck's Keytruda Gets FDA's Priority Tag in Bladder Cancer",
                "features": {
                    "keywords": [
                        "Merck",
                        "Keytruda",
                        "FDA",
                        "Priority",
                        "Bladder Cancer"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-12-24",
                "original_text": "Large-Cap Pharmaceuticals Industry Prospects Bright for 2020",
                "features": {
                    "keywords": [
                        "Large-Cap",
                        "Pharmaceuticals",
                        "Industry",
                        "Prospects",
                        "Bright",
                        "2020"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}